TP-2846

TP-2846 is a **synthetic tetracycline analog** developed as a novel antileukemia agent for the treatment of acute myeloid leukemia (AML). Originating from Tetraphase Pharmaceuticals, TP-2846 exhibits potent activity in both in vitro and in vivo cancer models, specifically targeting AML regardless of mutation or p53 status. Mechanistically, TP-2846 binds to the **mitochondrial ribosome**, inhibiting mitochondrial protein translation and inducing apoptosis. This results in antileukemic activity even in AML models resistant to standard treatments (e.g., anthracyclines, cytarabine, venetoclax). Its broad mechanism of action and potency warrant further investigation in oncology[4][5][7][9].